Riskpilot← Back to searchSign inGet full accessULSTRUP LÆGEHUS ApS
APSActiveCVR 79026816Teglværksvej 2ARental and operating of own or leased real estate · NACE 6820Est. 1984— employees
Revenue 2025
DKK 505K
+3% vs 2024
EBITDA margin
94.4%
+3% vs 2024
Equity ratio
27.6%
Financial strength
Net profit 2025
DKK 309K
+1% vs 2024
| Revenue | DKK 505K | +3% |
| EBITDA | DKK 477K | +3% |
| Net profit | DKK 309K | +1% |
| Total assets | DKK 3,2M | -3% |
| Equity | DKK 874K | +1% |
| Employees | — | — |
Legal name
ULSTRUP LÆGEHUS ApS
CVR number
79026816
Legal form
Anpartsselskab
NACE code
6820 · Rental and operating of own or leased real estate
Founded
20. december 1984
Share capital
DKK 210.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen
Company purpose
Selskabets formål er køb af fast ejendom samt udlejning heraf
Address
Teglværksvej 2A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 424 | 437 | 476 | 490 | 505 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 400 | 409 | 440 | 465 | 477 |
| Depreciation & amort. | -26 | -26 | -26 | -26 | -35 |
| EBIT | 374 | 383 | 414 | 439 | 442 |
| Net financials | -44 | -41 | -39 | -36 | -34 |
| Profit before tax | 330 | 341 | 375 | 402 | 408 |
| Tax | 78 | 81 | 89 | 97 | 99 |
| Net profit | 252 | 260 | 287 | 305 | 309 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2.785 | 2.616 | 2.464 | 3.274 | 3.167 |
| Equity | 1.010 | 927 | 860 | 865 | 874 |
| Long-term debt | 1.604 | 1.516 | 1.428 | 1.338 | 1.246 |
| Short-term debt | 171 | 173 | 177 | 1.071 | 1.047 |
| Total debt | 1.775 | 1.690 | 1.604 | 2.409 | 2.293 |
EBITDA margin
94.4%
This company
15.8%
Market median
+497% vs market
20212025
Equity ratio
27.6%
This company
38.2%
Market median
-28% vs market
20212025
Return on equity
35.4%
This company
18.4%
Market median
+92% vs market
20212025
Net profit margin
61.2%
This company
8.1%
Market median
+656% vs market
20212025
Asset turnover
0.16×
This company
1.12×
Market median
-86% vs market
20212025
Debt / equity
2.62×
This company
0.62×
Market median
-323% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
LW Management | Management | 1984 – 2000 |
PE Audit | Audit | 1984 – 2015 |
TS Management | Management | 1984 – 1996 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.33–49.99% | 33.33–49.99% | 1997 | |
| Individual | 33.33–49.99% | 33.33–49.99% | 2019 | |
| Individual | 33.33–49.99% | 33.33–49.99% | 2019 | |
| Individual | 33.33–49.99% | 33.33–49.99% | 1997 | |
| Individual | 33.33–49.99% | 33.33–49.99% | 1997 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ULSTRUP LÆGEHUS ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Würgler Hansen | Management | 0 companies |
| Poul Erik Sundstrup | Audit | 0 companies |
| Torben Schack | Management | 0 companies |